25650 Federal Register / Vol. 87, No. 84 / Monday, May 2, 2022 / Notices 

from participants who have registered to 

do so in advance. 

Preliminary Agenda and Other 

Meeting Information: A preliminary 

agenda will be posted by May 6 at 

https://ntp.niehs.nih.gov/go/

iccvamforum-2022. Interested 

individuals are encouraged to visit this 

web page to stay abreast of the most 

current meeting information. 

Webinar and Registration: This 

webinar is open to the public. 

Registration for the webinar is required 

and is open from April 11, 2022, 

through 4:00 p.m. EDT on May 27, 2022 

at https://ntp.niehs.nih.gov/go/ 

iccvamforum-2022. Interested 

individuals are encouraged to visit this 

web page to stay abreast of the most 

current meeting information. Registrants 

will receive instructions on how to 

access and participate in the webinar in 

the email confirming their registration. 

Request for Oral or Written Public 

Statements: In addition to time for 

clarifying or follow-up questions 

following scheduled presentations, time 

will be allotted during the meeting for 

oral public statements with associated 

slides on topics relevant to ICCVAM’s 

mission. Any participant registered for 

the webinar may ask clarifying 

questions during the appropriate times 

in the agenda. The additional 

registration is only required for those 

who wish to give separate public 

statements. Written public statements 

on topics relevant to ICCVAM’s mission 

will also be accepted. 

Separate registration for those wishing 

to provide oral public statements is 

required and is open from April 11, 

2022 through May 20, 2022 at https://

ntp.niehs.nih.gov/go/iccvamforum2022. The number and length of public 

statement presentations may be limited 

based on available time. Submitters will 

be identified by their name and 

affiliation and/or sponsoring 

organization, if applicable. Participants 

registered to present oral public 

statements must email their statement to 

ICCVAMquestions@niehs.nih.gov by 

May 20, 2022, to allow time for review 

by NICEATM and ICCVAM and posting 

to the meeting page prior to the forum. 

Persons presenting oral public 

statements will be contacted to arrange 

the logistics of their presentations. If 

participants registered to present oral 

public statements wish to use 

accompanying slides and/or submit 

supplementary written material, they 

must email these materials to 

ICCVAMquestions@niehs.nih.gov by 

May 20, 2022. This deadline is to allow 

time for review by NICEATM and 

ICCVAM and posting to the meeting 

page prior to the forum. 

Written statements on topics relevant 

to ICCVAM’s mission may be submitted 

to support an oral public statement or as 

standalone documents. These should be 

emailed to ICCVAMquestions@niehs.

nih.gov by May 20, 2022. Public 

statements received prior to the May 20, 

2022 deadline will be distributed to 

NICEATM and ICCVAM members 

before the meeting. Written public 

statements received after the deadline 

may be reviewed by NICEATM and 

ICCVAM at a future date. 

Materials submitted to accompany 

oral public statements or standalone 

written statements should include the 

submitters name, affiliation (if any), 

mailing address, telephone, email, and 

sponsoring organization (if any) with 

the document. National Toxicology 

Program guidelines for public 

statements are at http://

ntp.niehs.nih.gov/ntp/about_ntp/ 

guidelines_public_comments_508.pdf. 

Responses to this notice are 

voluntary. No proprietary, classified, 

confidential, or sensitive information 

should be included in statements 

submitted in response to this notice or 

presented during the meeting. This 

request for input is for planning 

purposes only and is not a solicitation 

for applications or an obligation on the 

part of the U.S. Government to provide 

support for any ideas identified in 

response to the request. Please note that 

the U.S. Government will not pay for 

the preparation of any information 

submitted or for its use of that 

information. 

Background Information on ICCVAM 

and NICEATM: ICCVAM is an 

interagency committee composed of 

representatives from 17 federal 

regulatory and research agencies that 

require, use, generate, or disseminate 

toxicological and safety testing 

information. ICCVAM conducts 

technical evaluations of new, revised, 

and alternative safety testing methods 

and integrated testing strategies with 

regulatory applicability. ICCVAM also 

promotes the scientific validation and 

regulatory acceptance of testing 

methods that more accurately assess the 

safety and hazards of chemicals and 

products and replace, reduce, or refine 

animal use. 

The ICCVAM Authorization Act of 

2000 (42 U.S.C. 285l–3) establishes 

ICCVAM as a permanent interagency 

committee of NIEHS and provides the 

authority for ICCVAM involvement in 

activities relevant to the development of 

alternative test methods. Additional 

information about ICCVAM can be 

found at https://ntp.niehs.nih.gov/go/

iccvam. 

NICEATM administers ICCVAM, 

provides scientific and operational 

support for ICCVAM-related activities, 

and conducts and publishes analyses 

and evaluations of data from new, 

revised, and alternative testing 

approaches. NICEATM and ICCVAM 

work collaboratively to evaluate new 

and improved testing approaches 

applicable to the needs of U.S. federal 

agencies. NICEATM and ICCVAM 

welcome the public nomination of new, 

revised, and alternative test methods 

and strategies for validation studies and 

technical evaluations. Additional 

information about NICEATM can be 

found at https://ntp.niehs.nih.gov/go/

niceatm. 

Dated: April 12, 2022. 

Brian R. Berridge, 

Associate Director, National Toxicology 

Program. 

[FR Doc. 2022–09357 Filed 4–29–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; R13 Conference 

Grant Applications. 

Date: June 30, 2022. 

Time: 10:00 a.m. to 12:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 2 

Democracy, 6707 Democracy Blvd., Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Jian Yang, Ph.D., Scientific 

Review Officer, Review Branch, Division of 

Extramural Activities, NIDDK, National 

Institutes of Health, Room 7011, 6707 

Democracy Boulevard, Bethesda, MD 20892– 

5452, (301) 594–7799, yangj@

extra.niddk.nih.gov. 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 84 / Monday, May 2, 2022 / Notices 25651 

* The Standards Council of Canada (SCC) voted 

to end its Laboratory Accreditation Program for 

Substance Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that program were 

accredited to conduct forensic urine drug testing as 

required by U.S. Department of Transportation 

(DOT) regulations. As of that date, the certification 

of those accredited Canadian laboratories will 

continue under DOT authority. The responsibility 

for conducting quarterly performance testing plus 

periodic on-site inspections of those LAPSAaccredited laboratories was transferred to the U.S. 

Continued 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: April 27, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–09383 Filed 4–29–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of HHS-Certified 

Laboratories and Instrumented Initial 

Testing Facilities Which Meet Minimum 

Standards To Engage in Urine and Oral 

Fluid Drug Testing for Federal 

Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies federal 

agencies of the laboratories and 

Instrumented Initial Testing Facilities 

(IITFs) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs using Urine or Oral Fluid 

(Mandatory Guidelines). 

FOR FURTHER INFORMATION CONTACT: 

Anastasia Donovan, Division of 

Workplace Programs, SAMHSA/CSAP, 

5600 Fishers Lane, Room 16N06B, 

Rockville, Maryland 20857; 240–276– 

2600 (voice); Anastasia.Donovan@

samhsa.hhs.gov (email). 

SUPPLEMENTARY INFORMATION: In 

accordance with Section 9.19 of the 

Mandatory Guidelines, a notice listing 

all currently HHS-certified laboratories 

and IITFs is published in the Federal 

Register during the first week of each 

month. If any laboratory or IITF 

certification is suspended or revoked, 

the laboratory or IITF will be omitted 

from subsequent lists until such time as 

it is restored to full certification under 

the Mandatory Guidelines. 

If any laboratory or IITF has 

withdrawn from the HHS National 

Laboratory Certification Program (NLCP) 

during the past month, it will be listed 

at the end and will be omitted from the 

monthly listing thereafter. 

This notice is also available on the 

internet at https://www.samhsa.gov/ 

workplace/resources/drug-testing/ 

certified-lab-list. 

The Department of Health and Human 

Services (HHS) notifies federal agencies 

of the laboratories and Instrumented 

Initial Testing Facilities (IITFs) 

currently certified to meet the standards 

of the Mandatory Guidelines for Federal 

Workplace Drug Testing Programs 

(Mandatory Guidelines) using Urine and 

of the laboratories currently certified to 

meet the standards of the Mandatory 

Guidelines using Oral Fluid. 

The Mandatory Guidelines using 

Urine were first published in the 

Federal Register on April 11, 1988 (53 

FR 11970), and subsequently revised in 

the Federal Register on June 9, 1994 (59 

FR 29908); September 30, 1997 (62 FR 

51118); April 13, 2004 (69 FR 19644); 

November 25, 2008 (73 FR 71858); 

December 10, 2008 (73 FR 75122); April 

30, 2010 (75 FR 22809); and on January 

23, 2017 (82 FR 7920). 

The Mandatory Guidelines using Oral 

Fluid were first published in the 

Federal Register on October 25, 2019 

(84 FR 57554) with an effective date of 

January 1, 2020. 

The Mandatory Guidelines were 

initially developed in accordance with 

Executive Order 12564 and section 503 

of Public Law 100–71 and allowed urine 

drug testing only. The Mandatory 

Guidelines using Urine have since been 

revised, and new Mandatory Guidelines 

allowing for oral fluid drug testing have 

been published. The Mandatory 

Guidelines require strict standards that 

laboratories and IITFs must meet in 

order to conduct drug and specimen 

validity tests on specimens for federal 

agencies. HHS does not allow IITFs to 

conduct oral fluid testing. 

To become certified, an applicant 

laboratory or IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a laboratory or IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and IITFs in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines using Urine and/ 

or Oral Fluid. An HHS-certified 

laboratory or IITF must have its letter of 

certification from HHS/SAMHSA 

(formerly: HHS/NIDA), which attests 

that the test facility has met minimum 

standards. HHS does not allow IITFs to 

conduct oral fluid testing. 

HHS-Certified Laboratories Approved 

To Conduct Oral Fluid Drug Testing 

In accordance with the Mandatory 

Guidelines using Oral Fluid dated 

October 25, 2019 (84 FR 57554), the 

following HHS-certified laboratories 

meet the minimum standards to conduct 

drug and specimen validity tests on oral 

fluid specimens: 

At this time, there are no laboratories 

certified to conduct drug and specimen 

validity tests on oral fluid specimens. 

HHS-Certified Instrumented Initial 

Testing Facilities Approved To Conduct 

Urine Drug Testing 

In accordance with the Mandatory 

Guidelines using Urine dated January 

23, 2017 (82 FR 7920), the following 

HHS-certified IITFs meet the minimum 

standards to conduct drug and specimen 

validity tests on urine specimens: 

Dynacare, 6628 50th Street NW, 

Edmonton, AB Canada T6B 2N7, 780– 

784–1190 (Formerly: GammaDynacare Medical Laboratories) 

HHS-Certified Laboratories Approved 

To Conduct Urine Drug Testing 

In accordance with the Mandatory 

Guidelines using Urine dated January 

23, 2017 (82 FR 7920), the following 

HHS-certified laboratories meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823 (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.) 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130 (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.) 

Clinical Reference Laboratory, Inc., 8433 

Quivira Road, Lenexa, KS 66215– 

2802, 800–445–6917 

Cordant Health Solutions, 2617 East L 

Street, Tacoma, WA 98421, 800–442– 

0438 (Formerly: STERLING Reference 

Laboratories) 

Desert Tox, LLC, 5425 E Bell Rd., Suite 

125, Scottsdale, AZ 85254, 602–457– 

5411/623–748–5045 

DrugScan, Inc., 200 Precision Road, 

Suite 200, Horsham, PA 19044, 800– 

235–4890 

Dynacare,* 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 


jspears on DSK121TN23PROD with NOTICES1